Takeda Gets Thumbs-Up on Subcutaneous Entyvio BLA

Takeda has another shot on goal for a self-administered subcutaneous form of its blockbuster Entyvio (vedolizumab) as maintenance treatment for patients with ulcerative colitis who have completed induction therapy with the antibody’s intravenous form.
Source: Drug Industry Daily